PubMed Journals Articles About "Sintilimab SBRT NSCLC Stage" RSS

09:31 EST 27th February 2020 | BioPortfolio

Sintilimab SBRT NSCLC Stage PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Sintilimab SBRT NSCLC Stage articles that have been published worldwide.

More Information about "Sintilimab SBRT NSCLC Stage" on BioPortfolio

We have published hundreds of Sintilimab SBRT NSCLC Stage news stories on BioPortfolio along with dozens of Sintilimab SBRT NSCLC Stage Clinical Trials and PubMed Articles about Sintilimab SBRT NSCLC Stage for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sintilimab SBRT NSCLC Stage Companies in our database. You can also find out about relevant Sintilimab SBRT NSCLC Stage Drugs and Medications on this site too.

Showing "Sintilimab SBRT NSCLC Stage" PubMed Articles 1–25 of 5,100+

Cone-beam CT radiomics features might improve the prediction of lung toxicity after SBRT in stage I NSCLC patients.

Stereotactic body radiotherapy (SBRT) is the standard care for inoperable early stage non-small cell lung cancer (NSCLC). The purpose of our study was to investigate whether a prediction model based on cone-beam CT (CBCT) plus pretreatment CT radiomics features could improve the prediction of tumor control and lung toxicity after SBRT in comparison to a model based on pretreatment CT radiomics features alone.

Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients with Early-Stage Non-Small Cell Lung Cancer.

Stereotactic body radiotherapy (SBRT) results in excellent local control of stage I non-small cell lung cancer (NSCLC). Radiobiology models predict greater tumor response when higher biologically effective doses (BED) are given. Prior studies support a BED ≥100 Gy with SBRT; however, data is limited comparing outcomes after various SBRT regimens. We therefore sought to evaluate national trends and the effect of using "low" versus "high" BED SBRT courses on overall survival (OS).

Stereotactic image-guided lung radiotherapy (SBRT) for clinical early-stage NSCLC: A long-term report from a multi-institutional database of patients treated with or without a pathologic diagnosis.

Early stage lung cancer is treated with stereotactic body radiotherapy (SBRT) in patients unfit or unwilling to undergo surgical resection. Some patients' comorbidities are so severe that they are unable to even undergo biopsy. Clinical diagnosis without biopsy before SBRT has been utilized, but there are limited data on its efficacy.

To biopsy or not to biopsy: A matched cohort analysis of early stage lung cancer treated with stereotactic radiation with or without histologic confirmation.

For non-operable stage I non-small cell lung cancer (NSCLC), stereotactic body radiation therapy (SBRT) has emerged as a standard treatment option. We aimed to compare the clinical outcomes of lung SBRT between patients with versus without pathological cancer diagnosis.

Cost-effectiveness of stereotactic body radiation therapy versus video assisted thoracic surgery in medically operable stage I non-small cell lung cancer: A modeling study.

Stage I non-small cell lung cancer (NSCLC) can be treated with either Stereotactic Body Radiotherapy (SBRT) or Video Assisted Thoracic Surgery (VATS) resection. To support decision making, not only the impact on survival needs to be taken into account, but also on quality of life, costs and cost-effectiveness. Therefore, we performed a cost-effectiveness analysis comparing SBRT to VATS resection with respect to quality adjusted life years (QALY) lived and costs in operable stage I NSCLC.

Surgical resection versus stereotactic body radiation therapy in early stage bronchopulmonary large cell neuroendocrine carcinoma.

Surgery is the standard of care for early stage non-small cell lung cancer (NSCLC). Stereotactic body radiotherapy (SBRT) is another definitive treatment option for those patients who have not been treated surgically. Comparison of approaches is being explored in NSCLC, but has yet to be compared exclusively in large cell neuroendocrine carcinoma (LCNEC) of the lung. We used the National Cancer Database (NCDB) to conduct such a comparison.

Mortality after radiotherapy or surgery in the treatment of early stage non-small-cell lung cancer: a population-based study on recent developments.

Stereotactic body radiotherapy (SBRT) can achieve high tumour control with limited toxicity for inoperable early stage non-small-cell lung cancer (NSCLC) patients.

Management of local recurrences and regional failure in early stage non-small cell lung cancer after stereotactic body radiation therapy.

Stereotactic body radiation therapy (SBRT) is a very effective way to treat early stage non-small cell lung cancer (NSCLC) and small oligometastatic lung lesions with consistently high rates of local control, but both local and regional/distant recurrences still occur. The management of recurrences remains unsettled and may entail repeat SBRT, conventionally fractionated external beam RT (EF-EBRT), chemotherapy or surgery. Most patients with local recurrences [within the initial planning target volume (PTV)...

A Matter of Comprehensive Informed Consent: Short-Term Mortality Rates With Definitive Treatment Options in Elderly Stage I NSCLC.

Although lobectomy is the standard of care in stage I non-small cell lung cancer (NSCLC), medical comorbidities increase surgical risk in elderly patients. No population-based studies compare short-term mortality (STM) for surgery (STM-S), radiation (STM-R), and observation (STM-O) in elderly patients with stage I NSCLC.

Predictors of Distant Recurrence Following Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.

The objective of this study was to characterize patients at an increased risk of distant metastasis (DM) following stereotactic body radiation therapy (SBRT) for stage I non-small cell lung cancer (NSCLC).

A national survey on technology and quality assurance for stereotactic body radiation therapy.

Stereotactic body radiation therapy (SBRT) for early stage solid tumors and metastases is increasing worldwide. In 2013, the Italian Association of Medical Physicists (AIFM) created a working group in order to standardize the SBRT dosimetric aspects (AIFM/SBRT-WG). The aim of this study was to investigate the current status of technology and quality assurance (QA) as regards SBRT in Italy. Clinical evaluation of SBRT was beyond the scope of the present study.

Comparison of Long-term Survival of Patients With Early-Stage Non-Small Cell Lung Cancer After Surgery vs Stereotactic Body Radiotherapy.

Previous comparisons of surgery and stereotactic body radiotherapy (SBRT) for early-stage (ES) non-small cell lung cancer (NSCLC) did not account for the extent of regional lymph node examination (LNE) during surgery.

One versus three fractions of stereotactic body radiation therapy for peripheral stage I-II non-small cell lung cancer: a randomized, multi-institution, phase 2 trial.

Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC) is a standard of care for medically inoperable patients. Our aim was to compare Common Terminology Criteria for Adverse Events (CTCAE) thoracic grade 3 or higher adverse events (AEs) of 30 Gy in one fraction (arm 1) vs. 60 Gy in 3 fractions (arm 2).

Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial.

Limited evidence is available on effectiveness of clinicoradiological follow-up of early-stage NSCLC patients. MAGRIT was a phase III adjuvant RCT conducted in surgically resected stage IB-IIIA NSCLC patients, in which all participants had a prospectively defined intensive clinicoradiological follow-up.

Brief report: Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - Update from PACIFIC.

In the phase 3 PACIFIC study of patients with unresectable, Stage III NSCLC without progression after chemoradiotherapy (CRT), durvalumab demonstrated significant improvements versus placebo in the primary endpoints of progression-free survival (HR, 0.52; 95% CI, 0.42-65; P

Concordance of Genomic Alterations by Next-generation Sequencing (NGS) in Tumor Tissue vs. Cell-free DNA in Stage I-IV Non-small Cell Lung Cancer.

Molecular biomarkers hold promise for the personalization of cancer treatment. However, a typical tumor biopsy may be difficult to acquire and may not capture genetic variations within or across tumors. Given these limitations, tumor genotyping using next-generation sequencing (NGS) of plasma-derived circulating tumor DNA (ctDNA) has the potential to transform non-small cell lung cancer (NSCLC) management. Importantly, mutations detected in biopsied tissue must also be detected in plasma-derived ctDNA at di...

Proton Beam Therapy for Histologically or Clinically Diagnosed Stage I Non-small Cell Lung Cancer (NSCLC): The First Nationwide Retrospective Study in Japan.

To investigate the efficacy and safety of proton beam therapy (PBT) for the treatment of Stage I non-small cell lung cancer (NSCLC).

PACIFIC: shifting tides in the treatment of locally advanced non-small cell lung cancer.

The treatment paradigm of stage III, unresectable non-small cell lung cancer (NSCLC) has had few advancement since concurrent chemoradiotherapy was established as standard of care treatment. Despite modifications to radiotherapy, chemotherapy and surgical approaches, loco-regional and distant relapse remain high, which unfortunately has translated to poor survival outcomes. The PACIFIC study introduced immunotherapy to the domain of stage III NSCLC and has emerged as the fourth pillar in cancer treatment fo...

Assessing the Variability and Quality of Lung Stereotactic Radiotherapy Treatment Plans using a Web-Based Crowdsourcing Platform.

The quality of stereotactic body radiation therapy (SBRT) treatment plans for early stage lung cancer are unknown outside of peer-reviewed publications. Thus, a study was conducted to crowdsource and analyze a variety of lung SBRT treatment plans from around the world.

The financial impact of SBRT for oligometastatic disease: A population-level analysis in Belgium.

There is a steady rise in Stereotactic Body RadioTherapy (SBRT) utilization in oligometastatic disease (OMD). This may generate important financial consequences for radiotherapy budgets. The National Institute for Health and Disability Insurance of Belgium (NIHDI) initiated a coverage with evidence development (CED) project for innovative radiotherapy, including SBRT, in 2011. A cost calculation and budget estimation for SBRT in the OMD setting was carried out.

Outcomes of surgery versus chemoradiotherapy in patients with clinical or pathologic stage N3 non-small cell lung cancer.

Because surgery is rarely recommended, there is minimal literature comparing the outcomes of surgery and chemoradiation in stage N3 non-small cell lung cancer (NSCLC). We examined the outcomes of definitive chemoradiation versus multimodality therapy, including surgery, for patients with clinical and pathologic stage N3 NSCLC.

SHARP hypofractionated stereotactic radiotherapy for localized prostate cancer: a biochemical response to treatment.

The standard treatment for patients with early-stage prostate cancer are operation and radiotherapy. Stereotactic body radiation therapy (SBRT) is one of the new radiotherapy methods. The aim of the study was to analyze tumor control of prostate cancer patients treated with SBRT.

Body mass index (BMI) Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC.

Metformin, a common medication used in the treatment of Diabetes Mellitus is known to have anti-cancer effects. We hypothesized that the salutary effect of metformin on the survival of patients with stage I NSCLC is influenced by body mass index (BMI).

Survival disparities following surgery among patients with different histological types of non-small cell lung cancer.

Clinical decisions for NSCLC patients are often based on TNM stage, which does not account for different histological subtype. Whether histological subtype affects survival still remains unclear. The main objective of this study was to determine the extent to which the survival outcomes of patients with early-stage NSCLC differ by histological subtype.

The application of nano-enrichment in CTC detection and the clinical significance of CTCs in non-small cell lung cancer (NSCLC) treatment.

Circulating tumor cells (CTCs) are an independent prognostic marker in non-small cell lung cancer (NSCLC). CTC numbers are closely related to early diagnosis, clinical stage, therapy surveillance, and prognosis of NSCLC. We used a more efficient nano-enrichment method to detect CTCs in NSCLC patients and explored the clinical value of CTCs. The results showed that CTC numbers in stage IV cases were significantly higher than those in stage I, II or III cases. The number of CTCs in poorly-differentiated cases...

Quick Search